Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene

FEBS Letters

Volumn 584, Issue 5, 2010, Pages 923-928

  Chevillard, Grégory ^a,b   Nouhi, Zaynab ^a,b   Anna, Derjuga ^a   Paquet, Marilène ^c   Blank, Volker ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Acute lung injury; Adipogenesis; BHT; Nrf3; Pparg

Indexed keywords

BUTYLCRESOL; CATALASE; FAS ANTIGEN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR NRF3; TRANSCRIPTION FACTOR PPARG2; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FATTY ACID SYNTHESIS; FEMALE; GENOTYPE; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; RESPIRATORY DISTRESS; TISSUE INJURY; TRANSCRIPTION REGULATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BUTYLATED HYDROXYTOLUENE; CATALASE; LUNG; MICE; MICE, MUTANT STRAINS; NF-E2-RELATED FACTOR 1; NF-E2-RELATED FACTOR 2;

MUS;

EID: 77049086081     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.01.028     Document Type: Article

References (25)

1. Ben Salem C., Hmouda H., and Bouraoui K. Acute lung injury and acute respiratory distress syndrome. Lancet 370 (2007) 383 author reply 384-385
2. Witschi H., Malkinson A.M., and Thompson J.A. Metabolism and pulmonary toxicity of butylated hydroxytoluene (BHT). Pharmacol. Ther. 42 (1989) 89-113
3. Kalin T., Meliton L., Meliton A., Zhu X., Whitsett J., and Kalinichenko V. Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the Foxf1 gene. Am. J. Respir. Cell Mol. Biol. 39 (2008) 390-399
4. Kalinichenko V.V., Zhou Y., Shin B., Stolz D.B., Watkins S.C., Whitsett J.A., and Costa R.H. Wild-type levels of the mouse forkhead box f1 gene are essential for lung repair. Am. J. Physiol. Lung Cell. Mol. Physiol. 282 (2002) L1253-L1265
5. Chan K., and Kan Y.W. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. USA 96 (1999) 12731-12736
6. Blank V., Hirsch E., Challis J.R., Romero R., and Lye S.J. Cytokine signaling, inflammation, innate immunity and preterm labour - a workshop report. Placenta 29 Suppl A (2008) S102-S104
7. Chenais B., Derjuga A., Massrieh W., Red-Horse K., Bellingard V., Fisher S.J., and Blank V. Functional and placental expression analysis of the human NRF3 transcription factor. Mol. Endocrinol. 19 (2005) 125-137
8. Massrieh W., Derjuga A., Doualla-Bell F., Ku C.Y., Sanborn B.M., and Blank V. Regulation of the MAFF transcription factor by proinflammatory cytokines in myometrial cells. Biol. Reprod. 74 (2006) 699-705
9. Nouhi Z., Chevillard G., Derjuga A., and Blank V. Endoplasmic reticulum association and N-linked glycosylation of the human Nrf3 transcription factor. FEBS Lett. 581 (2007) 5401-5406
10. Zhang Y., Kobayashi A., Yamamoto M., and Hayes J. The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence. J. Biol. Chem. 284 (2009) 3195-3210
11. Derjuga A., Gourley T.S., Holm T.M., Heng H.H., Shivdasani R.A., Ahmed R., Andrews N.C., and Blank V. Complexity of CNC transcription factors as revealed by gene targeting of the Nrf3 locus. Mol. Cell Biol. 24 (2004) 3286-3294
12. Aebi H. Catalase in vitro. Methods Enzymol. 105 (1984) 121-126
13. Schrader M., and Fahimi H.D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta 1763 (2006) 1755-1766
14. Kwak M., Itoh K., Yamamoto M., and Kensler T. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell Biol. 22 (2002) 2883-2892
15. Zhang Y., Lucocq J.M., Yamamoto M., and Hayes J.D. The N-terminal homology box 1 (NHB1) sequence in transcription factor Nrf1 is required to anchor it to the endoplasmic reticulum and also to enable its Asn-glycosylation. Biochem. J. (2007)
16. Erovic B.M., Woegerbauer M., Pammer J., Selzer E., Grasl M., and Thurnher D. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur. J. Clin. Invest. 38 (2008) 61-66
17. Sherratt P.J., McLellan L.I., and Hayes J.D. Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents. Biochem. Pharmacol. 66 (2003) 51-61
18. Lin H.M., Yen F.L., Ng L.T., and Lin C.C. Protective effects of Ligustrum lucidum fruit extract on acute butylated hydroxytoluene-induced oxidative stress in rats. J. Ethnopharmacol. 111 (2007) 129-136
19. Conacher H., Iverson F., Lau P., and Page B. Levels of BHA and BHT in human and animal adipose tissue: interspecies extrapolation. Food Chem. Toxicol. 24 (1986) 1159-1162
20. Latasa M.J., Griffin M.J., Moon Y.S., Kang C., and Sul H.S. Occupancy and function of the -150 sterol regulatory element and -65 E-box in nutritional regulation of the fatty acid synthase gene in living animals. Mol. Cell Biol. 23 (2003) 5896-5907
21. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
22. Hill M., Young M., McCurdy C., and Gimble J. Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology 138 (1997) 3073-3076
23. Liu D., Zeng B., and Shang Y. Decreased expression of peroxisome proliferator-activated receptor gamma in endotoxin-induced acute lung injury. Physiol. Res. 55 (2006) 291-299
24. Paola R., and Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury. PPAR Res. 2007 (2007) 63745
25. Becker J., Delayre-Orthez C., Frossard N., and Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fundam. Clin. Pharmacol. 20 (2006) 429-447